Wall Street analyst estimates for enVVeno Medical Corporation (NVNO): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
enVVeno Medical Corporation, based in Irvine, California, is a medical device firm founded in 1999 that is currently in its clinical development phase. The company's primary objective is to pioneer advanced bioprosthetic, tissue-engineered solutions intended to significantly elevate the existing standards of care for patients suffering from venous conditions.
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-10-30 | $-3.27 | ||
| 2026-07-30 | $-5.37 | $-4.69 | -14.5% |
| 2026-05-07 | $-5.89 | $-8.40 | +29.9% |
| 2026-03-26 | $-227.07 | $-9.80 | -2217.0% |
| 2025-10-29 | $-281.75 | $-10.50 | -2583.3% |
| 2025-07-30 | $-11.55 | $-9.80 | -17.9% |
| 2025-04-30 | $-7.70 | $-11.90 | +35.3% |
| 2025-02-28 | $-0.35 | $-0.35 | +0.0% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $785912 | $422111 | $186552 | $31243 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | $961468 | $558872 | 0 | 0 | $383972 | $452909 | $525000 | $546000 | $528000 | 0 |
| Gross Profit | -$175556 | -$136761 | $186552 | $31243 | -$383972 | -$452909 | -$525000 | -$546000 | -$528000 | 0 |
| Research & Development | 0 | $649736 | $1.2M | $2.2M | $4.3M | $5.7M | $9.9M | $13.6M | $12.2M | $10.0M |
| Selling, General & Admin | $4.5M | $5.3M | $6.3M | $4.5M | $4.5M | $10.7M | $14.5M | $11.1M | $11.0M | $10.9M |
| Operating Expenses | $4.5M | $6.0M | $8.0M | $7.7M | $8.8M | $16.4M | $24.4M | $24.7M | $23.3M | $20.9M |
| Operating Income | -$4.7M | -$6.1M | -$7.9M | -$7.7M | -$9.1M | -$16.9M | -$24.9M | -$25.2M | -$23.8M | -$20.9M |
| EBITDA | -$5.4M | -$5.7M | -$6.0M | -$7.2M | -$8.8M | -$16.1M | -$24.1M | -$23.0M | -$21.3M | -$19.0M |
| Interest Expense | $57890 | $1.9M | $6.9M | $933 | -$3739 | 0 | 0 | 0 | 0 | 0 |
| Pre-tax Income | -$5.6M | -$7.8M | -$13.0M | -$7.6M | -$9.1M | -$16.5M | -$24.7M | -$23.5M | -$21.8M | -$19.5M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$5.9M | -$7.8M | -$13.0M | -$7.6M | -$9.1M | -$16.5M | -$24.7M | -$23.5M | -$21.8M | -$19.5M |
| EPS | $-10412.50 | $-26068.00 | $-53495.75 | $-14822.50 | $-9236.50 | $-2327.50 | $-2695.00 | $-2339.75 | $-1555.75 | $-33.06 |
| EPS (Diluted) | $-10412.50 | $-26068.00 | $-53495.75 | $-14822.50 | $-9236.50 | $-2327.50 | $-2695.00 | $-2339.75 | $-1555.75 | $-33.06 |
| Shares Outstanding (Diluted) | $358 | $316 | $306 | $515 | $1054 | $7086 | $9167 | $10042 | $13993 | $589000 |
Price
| Price | $9.05 |
| Market Cap | $0M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ADGM · AEMD · ALUR · AYTU · COCH · CODX · EKSO
Explore sector: Healthcare · Medical - Devices
More sections of NVNO: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks